Adding an Immunotherapy Drug to the Usual Chemotherapy Treatment for Stage II-III Breast Cancer

Short Title: S2206

Enrollment Status: Recruiting

NCT #: NCT06058377

Specialty Area: Oncology

Condition Studied: Early Stage Breast Cancer

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out if adding durvalumab (an immunotherapy medication) to standard chemotherapy helps prevent breast cancer from returning in patients with MP2 stage II–III hormone receptor-positive, HER2-negative breast cancer.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with hormone receptor-positive (HR+) and HER2-negative breast cancer
Stage II or III
Must have a MammaPrint High 2 Risk (MP2) result

What's Involved

Participation in the study will include:

Chemotherapy (paclitaxel, doxorubicin, and cyclophosphamide) with our without durvalumab given intravenously (IV)
Genetic testing and biospecimen collection
Mammograms to monitor response to treatment
Quality-of-life (QOL) assessments
Blood and urine tests to monitor your health and treatment effects
Electrocardiogram (ECG) to monitor heart function
Questionnaires

Principal Investigator

Lee Schwartzberg, MD

Oncology

A Member of

(775) 982–5000

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06058377

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews